• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Quality of Acute Ischemic Stroke Care in Thailand: A Prospective Multicenter Countrywide Cohort Study
Conclusions: Limited access to acute ischemic stroke care interventions were observed in many domains especially thrombolysis and stroke unit admission. These findings emphasize an urgent need for strategies to improve standard acute stroke care among developing countries.
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2013 Category: Neurology Authors: Yongchai Nilanont, Samart Nidhinandana, Nijasri C. Suwanwela, Suchat Hanchaiphiboolkul, Taksin Pimpak, Pyatat Tatsanavivat, Gustavo Saposnik, Niphon Poungvarin, Thai Stroke Registry Tags: Original Articles Source Type: research

Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke
Conclusions: In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.
Source: Journal of Stroke and Cerebrovascular Diseases - August 11, 2011 Category: Neurology Authors: Alexandros L. Georgiadis, Steve M. Cordina, Gabriela Vazquez, Nauman Tariq, M. Fareed K. Suri, Kamakshi Lakshminarayan, Harold P. Adams, Adnan I. Qureshi Tags: Original Articles Source Type: research

Primary Prophylactic Aspirin Use and Incident Stroke: Reasons for Geographic and Racial Differences in Stroke Study
Conclusions: In this observational study, prophylactic aspirin use was not associated with risk of first stroke, and there were no sex, race, or regional differences.
Source: Journal of Stroke and Cerebrovascular Diseases - April 8, 2013 Category: Neurology Authors: Stephen P. Glasser, Martha K. Hovater, Daniel T. Lackland, Mary Cushman, George Howard, Virginia J. Howard Tags: Original Articles Source Type: research

Short-term Bleeding Events Observed with Clopidogrel Loading in Acute Ischemic Stroke Patients
Discussion: Contrary to our original hypothesis, patients with AIS receiving clopidogrel loading doses within 24 hours of symptom onset did not appear to experience a higher rate of new serious bleeding events during acute hospitalization when compared with patients who did not receive loading doses. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke trial is expected to provide insight into the safety of clopidogrel loading as an acute intervention after cerebral ischemia.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Lester Y. Leung, Karen C. Albright, Amelia K. Boehme, Joseph Tarsia, Kamal R. Shah, James E. Siegler, Erica M. Jones, Gayle R. Pletsch, Timothy M. Beasley, Sheryl Martin-Schild Tags: Original Articles Source Type: research

A Comparative Study of Dual versus Monoantiplatelet Therapy in Patients with Acute Large-Artery Atherosclerosis Stroke
Background: Antiplatelet drugs are recommended for patients with acute noncardioembolic stroke. However, few randomized clinical trials have investigated the safety and efficacy of dual antiplatelet therapy for these patients. The aim of this study was to evaluate the effects of treatment with clopidogrel and aspirin (combination therapy) and aspirin alone (monotherapy) on neurologic deterioration, platelet activation, and other short-term outcomes in patients with acute large-artery atherosclerosis stroke.Materials and Methods: Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were random...
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2014 Category: Neurology Authors: Xingyang Yi, Jing Lin, Chun Wang, Biao Zhang, Wanzhang Chi Tags: Original Articles Source Type: research

Thrombocytopenia and In-hospital Mortality Risk among Ischemic Stroke Patients
Background: Thrombocytopenia has been associated with increased mortality in nonstroke conditions. Because its role in acute ischemic stroke is less well understood, we sought to determine whether thrombocytopenia at admission for acute ischemic stroke was associated with in-hospital mortality.Methods: We used data from a retrospective cohort of stroke patients (1998-2003) at 5 U.S. hospitals. Risk factors considered included conditions that can lead to thrombocytopenia (e.g., liver disease), increase bleeding risk (e.g., hemophilia), medications with antiplatelet effects (e.g., aspirin), and known predictors of mortality ...
Source: Journal of Stroke and Cerebrovascular Diseases - September 12, 2012 Category: Neurology Authors: Jason J. Sico, Michael S. Phipps, John Concato, Carolyn K. Wells, Albert C. Lo, Steven E. Nadeau, Linda S. Williams, Aldo J. Peixoto, Mark Gorman, John L. Boice, Dawn M. Bravata Tags: Original Articles Source Type: research

Warfarin versus Aspirin for Prevention of Stroke in Heart Failure: A Meta-analysis of Randomized Controlled Clinical Trials
Conclusions: Compared with aspirin, warfarin reduced the risk of stroke while conferring an increased risk of major hemorrhage. Warfarin does not increase mortality or confer an increased risk of ICH compared with aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - November 21, 2012 Category: Neurology Authors: Gyanendra Kumar, Munish Kumar Goyal Tags: Original Articles Source Type: research

“Aspirin Resistance” in Ischemic Stroke: Insights Using Short Thrombelastography
Conclusion: This study demonstrates that although COX-1 activity is adequately and consistently suppressed by aspirin in stroke patients, this effect is not reliably indicated by whole-blood clotting in response to AA. These data help to explain why the reported prevalence of aspirin resistance in stroke from studies employing AA-induced platelet reactivity is high and cast doubt on the veracity of such reports.
Source: Journal of Stroke and Cerebrovascular Diseases - July 8, 2013 Category: Neurology Authors: Nalyaka Sambu, Ashwin Radhakrishnan, Nicola Englyst, Nicolas Weir, Nick Curzen Tags: Original Articles Source Type: research

Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project
Diabetes mellitus is associated with an increased risk of stroke and poor outcome following a stroke event. We assessed the impact of discharge treatment with aspirin versus clopidogrel on the 10-year survival of patients with type 2 diabetes after a first-ever noncardioembolic acute ischemic stroke (AIS).
Source: Journal of Stroke and Cerebrovascular Diseases - July 28, 2017 Category: Neurology Authors: Haralampos Milionis, George Ntaios, Vasileios Papavasileiou, Konstantinos Spengos, Efstathios Manios, Moses Elisaf, Konstantinos Vemmos Source Type: research

Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial
Dual antiplatelet therapy, with combination aspirin and clopidogrel, is now standard of care in the secondary prevention of minor stroke and transient ischemic attack1 –3 as well as stroke due to intracranial atherosclerotic disease.4 However, in the Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE)2 and Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)3 randomized clinical trials, determination of the etiology of ischemic stroke was not required to initiate secondary prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Zachary Bulwa, Faddi G. Saleh Velez, James R. Brorson, Camila B. Pinto Source Type: research

Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review
Ticagrelor is a potent P2Y12 receptor antagonist that may have a role in acute ischemic stroke (AIS), particularly in patients with symptomatic atherosclerotic disease.1,2 Recently, a large randomized control trial demonstrated a significant reduction in stroke or death within 30 days following minor stroke or TIA with ticagrelor plus aspirin versus aspirin alone.3 Studies of ticagrelor have focused on patients with minor stroke or TIA; however, safety of ticagrelor following more severe ischemic strokes is unknown.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2021 Category: Neurology Authors: Stephen W. English, David R. Landzberg, Nirav R. Bhatt, Michael R. Frankel, Digvijaya Navalkele Source Type: research

Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy
Stroke causes long-term serious disability with global prevalence of 101 million people in 2019.1 Antithrombotic therapy is recommended for stroke secondary prevention depending on the acute ischemic stroke (AIS) subtype.2 One of the major causes of non-cardioembolic AIS is intracranial atherosclerosis, which requires single antiplatelet therapy (SAPT), mostly with aspirin.3,4 Dual antiplatelet therapy (DAPT) may reduce the risk of non-cardioembolic stroke by 29% in AIS attributable to severe intracranial stenosis when used for a limited period of time.
Source: Journal of Stroke and Cerebrovascular Diseases - November 16, 2022 Category: Neurology Authors: Gabriela Rusin, Jadwiga Kubica, Krzysztof Piotr Malinowski, Agnieszka S łowik, Anetta Undas Source Type: research

Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100® and VerifyNow®
Background: The prevalence of ex vivo high on-treatment platelet reactivity (HTPR) to commonly prescribed antiplatelet regimens after transient ischemic attack (TIA) or ischemic stroke is uncertain.Methods: Platelet function inhibition was simultaneously assessed with modified light transmission aggregometry (VerifyNow; Accumetrics Inc, San Diego, CA) and with a moderately high shear stress platelet function analyzer (PFA-100; Siemens Medical Solutions USA, Inc, Malvern, PA) in a pilot, cross-sectional study of TIA or ischemic stroke patients. Patients were assessed on aspirin–dipyridamole combination therapy (n = 51) o...
Source: Journal of Stroke and Cerebrovascular Diseases - September 14, 2012 Category: Neurology Authors: Justin A. Kinsella, W. Oliver Tobin, Dermot Cox, Tara Coughlan, Ronan Collins, Desmond O’Neill, Raymond P. Murphy, Dominick J.H. McCabe Tags: Original Articles Source Type: research

Hemorrhagic Risk of Emergent Endovascular Treatment Plus Stenting in Patients with Acute Ischemic Stroke
Conclusions: Our findings suggest that emergent stenting in endovascular treatment of AIS is associated with SICH.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2013 Category: Neurology Authors: Laura Dorado, Carlos Castaño, Mònica Millán, Aitziber Aleu, Natàlia Pérez de la Ossa, Meritxell Gomis, Elena López-Cancio, Elio Vivas, Ana Rodriguez-Campello, Mar Castellanos, Antoni Dávalos Tags: Original Articles Source Type: research

The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke
In this study, we evaluated the effect of antiplatelet use on clinical stroke severity and ischemic lesion volume, and assessed the confounding effect of laboratory-defined aspirin resistance on this relationship.
Source: Journal of Stroke and Cerebrovascular Diseases - November 11, 2015 Category: Neurology Authors: Nergiz Agayeva, Mehmet Akif Topcuoglu, Ethem Murat Arsava Source Type: research

Pages: 1  2  3  4  5